REN and diabetes mellitus: This meta-analysis is the first to examine the efficacy and safety of aliskiren in trial patients with high-risk diabetes, a group where renin–angiotensin system (RAS) inhibition reduces cardiovascular outcomes.18 We compare use of aliskiren with placebo or single ACEi/ARB in patients with diabetes.